OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Jill Wechsler is Pharm Exec's Washington Corespondent
Pharmaceutical Executive
April 21, 2016.
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in Applied Clinical Trials.
Related Content:
Technology